Stockreport

Largest Prospective Study to Date Further Supports Performance of DecisionDx®-UM for Metastatic Risk Stratification in Uveal Melanoma and Utility of PRAME Biomarker for Refining Risk When ...

Castle Biosciences, Inc. - Common stock  (CSTL) 
Last castle biosciences, inc. - common stock earnings: 3/10 04:05 pm Check Earnings Report
PDF Oral presentation at ARVO shares ground-breaking findings from the ongoing Collaborative Ocular Oncology Group (COOG) study 2 (COOG2) of patients with uveal melanoma (UM [Read more]